Chat message

Slack / Private Message Drop, pp.103-104 [SLACK_000317] · slack_pm:msg:01050

Date: 2020-07-23 08:44
Type: chat message · slack
recipient: Robert F. Garry, Edward C. Holmes, Andrew Rambaut
speaker: Kristian G. Andersen

Recipients on this medium are inferred from channel membership, not per-message addressing.

Yeah, NIAID asked us about getting an isolate from a "mild infection"... Well, mild, severe, moderate, chances are they're all the same. I agree on getting something as basal on the tree as possible (that's assuming D614G _does not_ show resistance to neutralization - which is a real concern (e.g., GP A82V in Ebola does that).

In context

A single line often inverts meaning once you see what it answers, so neighbouring messages are always shown.

2020-07-23 07:35 Kristian G. Andersen open

Might be worth tuning in for: https://twitter.com/CellPressNews/status/1286096187754459142?s=20 @Robert Garry, we need to discuss challenge trials at some point :wink:.
2020-07-23 07:49 Robert F. Garry open

Wow - that Cell discussion with Gao and Shi should be fun...Not sure I can bring you over to the "dark side" and Ithink it is possible someone could die, but - yeah IMO - controlled trials better than "wild" trials given the circumstances.
2020-07-23 07:56 Kristian G. Andersen open

Yeah, should be interesting. George popped up on a NASEM meeting last week and it was pretty interesting to get his take. A little different than here in the US... I say we just make the whole of Florida a challenge trial :wink:
2020-07-23 08:14 Andrew Rambaut open

I am talking to Wellcome Vaccines dept tomorrow about challenge trials. They are considering which stocks to manufacture. I am not that sure what to tell them other than a basal D614G.
2020-07-23 08:44 Kristian G. Andersen

Yeah, NIAID asked us about getting an isolate from a "mild infection"... Well, mild, severe, moderate, chances are they're all the same. I agree on getting something as basal on the tree as possible (that's assuming D614G _does not_ show resistance to neutralization - which is a real concern (e.g., GP A82V in Ebola does that).
2020-07-23 08:45 Andrew Rambaut open

Jeremy's preprint suggests it is sensitive to ABs
2020-07-23 08:45 Andrew Rambaut open

But I guess the point is it is the dominant form and will remain so.
2020-07-23 08:45 Kristian G. Andersen open

The UK has been playing hard and loose with viruses in the past, so I wouldn't be surprised if we'd see challenge trials from them. IMO, this virus is much too dangerous with too many uncertain long-term effects to deliberately infect people - especially given the HUGE number of cases we have in this country.
2020-07-23 08:46 Kristian G. Andersen open

Yeah, everything is basically D614G by now, so that's kinda the virus we need to make sure the vaccine works against - but I'm not really concerned there's a difference between Doug and Dougless here.

Full conversation →